Abstract
Physical exercise (PE) as antidepressive intervention is a promising alternative, as shown by multiple meta-analyses. However, there is no consensus regarding optimal intensity and duration of exercise, and there are no objective criteria available for personalized indication of treatment. The aims of this study were (1) to evaluate whether individual activity patterns before intervention can predict the response to treatment; and (2) to evaluate whether the patient outcome can be improved by using prior information on treatment efficacy at individual level. The study included subjects with mild to moderate depression randomized to three levels of exercise intensity in the Regassa study. Using a previously developed pipeline for data analysis, we have generated linear regression ensembles to predict the response to treatment using features extracted from actigraphy recordings. To understand the contribution of individual features, we performed a Bayesian analysis of coefficients, and found that different levels of PE intensity yield distinct signatures in enriched feature subsets. Next, we used the trained ensembles for a counterfactual analysis of response and remission rate provided prior knowledge of response to treatment outcome. The response to either PE regime was estimated for all patients, irrespective of original treatment assignment. Each patient was then virtually allocated to the PE regime predicted to yield best outcome, and the response and remission rates were compared against simulated random assignment to treatment. The counterfactual analysis showed that assignment to best individual PE regime yields significantly higher (increase by 28%) remission rates as compared to random assignment to treatment, which is accounted for by improved response in about 32% of the patients as compared to observed treatment outcome. While it is not possible to claim individual protocol optimization, our data suggest it may be possible to identify a PE regime to yield the best results for a patient based on individual circadian patterns of activity.
Competing Interest Statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: SS and SC are co-inventors on US Patent No. 10,731,216, and co-founders of NorthernLight Diagnostics AB. YF has no conflict of interest to declare.
Clinical Trial
DRKS00008745
Clinical Protocols
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study received ethical approval from Stockholm regional ethical review board (Dnr: 2010/1779-31/4)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Clarity in description of Materials and Methods. Clarity in description of Results. Typos, missing reference to Fig. 1.
Data Availability
Data cannot be shared publicly because of the sensitive nature of medical classification.
